| Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer (NCT02245100) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-07-22 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection (NCT01249443) | AIDS Malignancy Consortium | 2013-11-01 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT01816984) | University of Chicago | 2013-05-01 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer (NCT01847326) | University of Chicago | 2013-03-26 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (NCT01528137) | Stanford University | 2012-05-01 |
| Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (NCT01283178) | Virginia Commonwealth University | 2011-07-01 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (NCT01334177) | University of Washington | 2011-06-01 |
| Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy (NCT01332279) | Fox Chase Cancer Center | 2011-04-01 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (NCT01316757) | Fox Chase Cancer Center | 2011-02-16 |
| Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (NCT01254617) | National Cancer Institute (NCI) | 2011-02-10 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (NCT01256385) | National Cancer Institute (NCI) | 2010-11-01 |
| Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck (NCT01044433) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (NCT00939627) | National Cancer Institute (NCI) | 2009-07-01 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT00588770) | National Cancer Institute (NCI) | 2008-08-08 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT00906360) | National Cancer Institute (NCI) | 2008-07-01 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. (NCT01469429) | Ohio State University Comprehensive Cancer Center | 2007-09-04 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00507767) | National Cancer Institute (NCI) | 2007-07-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (NCT00458978) | National Cancer Institute (NCI) | 2007-02-01 |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT00098631) | National Cancer Institute (NCI) | 2004-10-01 |
| S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00096512) | National Cancer Institute (NCI) | 2004-10-01 |
| Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck (NCT00081211) | National Cancer Institute (NCI) | 2004-04-01 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00055913) | National Cancer Institute (NCI) | 2003-03-01 |
| Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck (NCT00033618) | National Cancer Institute (NCI) | 2002-11-01 |